Clinical Trials Directory

Trials / Terminated

TerminatedNCT00379860

Study Evaluation LXR-623 in Healthy Adults

A Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of LXR-623 Administered Orally to Healthy Subjects

Status
Terminated
Phase
Phase 1
Study type
Interventional
Enrollment
—
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer · Industry
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

To evaluate the safety and tolerability of multiple doses of LXR in healthy adults.

Conditions

Interventions

TypeNameDescription
DRUGLXR-623

Timeline

Start date
2006-10-01
Completion
2007-01-01
First posted
2006-09-25
Last updated
2007-03-09

Source: ClinicalTrials.gov record NCT00379860. Inclusion in this directory is not an endorsement.

Study Evaluation LXR-623 in Healthy Adults (NCT00379860) · Clinical Trials Directory